secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0001641172-25-009681
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncocyte Q1 revenue $2.14M, gross margin 62%; transplant trial gets IRB approval
--------------------------------------------------------------------------------

- Q1 2025 pharma services revenue $2.14M with 62% gross margin, up from 40% in Q4 2024.
- Net loss $6.7M ($0.26 per share); non-GAAP loss from operations $5.0M.
- Clinical trial design completed, central IRB approved; three top-10 US transplant centers expected to participate.
- Ten leading transplant centers now using GraftAssure RUO kits; company plans to rename in Q2.
- Cash balance $32.7M at quarter-end, including $28.7M net from February offering; Q1 operating cash use $5.9M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000164117225009681/0001641172-25-009681-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000164117225009681/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-009681

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer